2021
DOI: 10.1016/j.intimp.2021.107575
|View full text |Cite
|
Sign up to set email alerts
|

The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 14 publications
(8 citation statements)
references
References 50 publications
0
8
0
Order By: Relevance
“…Although a large number of studies have shown that metformin treatment can reduce inflammation, delay disease progression, protect bone tissue, and improve metabolic dysfunction and immune system function in the progression of RA [ 24 , 50 , 51 , 52 , 53 , 54 ], few studies focus on the relationship between metformin treatment and the risk of RA. In an 18-year retrospective cohort study, Naffaa found that adherence to metformin therapy reduced the risk of RA, but this conclusion was limited to women alone [ 26 ].…”
Section: Discussionmentioning
confidence: 99%
“…Although a large number of studies have shown that metformin treatment can reduce inflammation, delay disease progression, protect bone tissue, and improve metabolic dysfunction and immune system function in the progression of RA [ 24 , 50 , 51 , 52 , 53 , 54 ], few studies focus on the relationship between metformin treatment and the risk of RA. In an 18-year retrospective cohort study, Naffaa found that adherence to metformin therapy reduced the risk of RA, but this conclusion was limited to women alone [ 26 ].…”
Section: Discussionmentioning
confidence: 99%
“…Adherence to metformin treatment was associated with a reduced risk of RA during an 18-year follow-up in a nationwide retrospective cohort study [ 64 ]. In a randomized, double-blind, placebo-controlled clinical trial, patients with active RA were treated with additional metformin (1,000 mg/day) or placebo on background methotrexate therapy [ 65 ]. After 12 weeks of treatment, metformin-treated patients showed better clinical outcomes than placebo-treated patients, reflected in significant improvement in disease activity and higher rates of remission [ 65 ].…”
Section: Therapeutic Effects Of Metformin In Rheumatoid Arthritismentioning
confidence: 99%
“…In a randomized, double-blind, placebo-controlled clinical trial, patients with active RA were treated with additional metformin (1,000 mg/day) or placebo on background methotrexate therapy [ 65 ]. After 12 weeks of treatment, metformin-treated patients showed better clinical outcomes than placebo-treated patients, reflected in significant improvement in disease activity and higher rates of remission [ 65 ]. These results indicate that metformin could be a beneficial adjunctive therapy in RA.…”
Section: Therapeutic Effects Of Metformin In Rheumatoid Arthritismentioning
confidence: 99%
“…In an Israeli cohort, patients on high-dose (2,550 mg/day) metformin had a lower risk of developing RA than those on low-dose (850 mg/day) metformin (adjusted hazard ratio of 0.62, 95% confidence interval 0.46-0.84), especially in women (184). A randomized controlled trial shows that RA patients treated with metformin for 12 weeks (80.8%) had significantly higher rates of pain reduction and decreased disease activity than those treated with placebo (54.7%) (185). No serious adverse effects were reported in these two groups.…”
Section: Metforminmentioning
confidence: 99%